Publications Publications Journal for ImmunoTherapy of Cancer: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 Aug 10, 2019 Oncolytic immunotherapy: An emerging new modality for the treatment of cancer May 01, 2016 Infectious Enthusiasm Feb 29, 2016 Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Feb 01, 2016 Print Page RSS Feeds RSS Feeds Email Alerts Email Alerts Contact IR Contact IR Search Search
Publications Journal for ImmunoTherapy of Cancer: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 Aug 10, 2019 Oncolytic immunotherapy: An emerging new modality for the treatment of cancer May 01, 2016 Infectious Enthusiasm Feb 29, 2016 Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Feb 01, 2016
Journal for ImmunoTherapy of Cancer: Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1 Aug 10, 2019
Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Feb 01, 2016
